Compare BOC & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOC | ENTA |
|---|---|---|
| Founded | 2009 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 413.9M | 407.5M |
| IPO Year | 2017 | 2013 |
| Metric | BOC | ENTA |
|---|---|---|
| Price | $12.53 | $15.44 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $25.00 | $20.40 |
| AVG Volume (30 Days) | 190.5K | ★ 304.7K |
| Earning Date | 11-13-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $112,601,970.00 | $65,324,000.00 |
| Revenue This Year | $6.29 | $0.99 |
| Revenue Next Year | $5.09 | $0.19 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.22 | N/A |
| 52 Week Low | $11.30 | $4.09 |
| 52 Week High | $15.75 | $15.34 |
| Indicator | BOC | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.57 | 68.21 |
| Support Level | $13.41 | $14.07 |
| Resistance Level | $13.83 | $15.28 |
| Average True Range (ATR) | 0.36 | 0.81 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 2.26 | 79.86 |
Boston Omaha Corp is a United States based company which invests in real estate. Its operations include its ownership of multiple billboards in Florida, Georgia, Wisconsin, and Alabama and equity method investments in several real estate companies. The company operates four separate lines of business, outdoor billboard advertising, the broadband services industry, the insurance industry, and the asset management industry. Company generate revenue from outdoor advertising through the leasing of advertising space on billboards. It also generate revenue from commissions on surety bond sales and account for commissions and principally from internet services and is recognized on a straight-line basis over the term of the contract in the period the services are rendered.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.